SNB advises Boehringer Ingelheim on the acquisition of Labor Dr. Merk & Kollegen GmbH

With the transaction, which was completed on March 15, 2021, Boehringer Ingelheim has acquired the virology competence center Labor Dr. Merk & Kollegen GmbH in Ochsenhausen. Founded in 1971, the family-owned company is located in close to Boehringer Ingelheim's largest research and development site in Biberach, Germany, and has established a GMP virus production facility in recent years. With the acquisition, Boehringer Ingelheim strengthens its research & development and clinical manufacturing capabilities for ATMP (advanced therapy medicinal products) in the field of immuno-oncology.

Boehringer Ingelheim was supported for the first time by the Hamburg office of SNB (Dr. Mark-Alexander Huth, Nils Bräuninger, Johannes Thies) in the legal aspects of the transaction preparation and support as well as in the contract negotiations.

Go back

Ihr Browser ist veraltet

Aktualisieren sie bitte ihren Browser um diese Webseite ohne Probleme anzuzeigen.

Your browser is outdated

You have to update your browser to view this webseite without any problems